Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain drug
Biotech
Vertex's phase 3 pain trials hit goals but fail to beat Vicodin
Vertex’s attempt to crack the blockbuster pain market has delivered a pair of phase 3 wins. And yet, the positive news was tempered by a key failure.
Nick Paul Taylor
Jan 30, 2024 8:00am
Drug more effective on pain than gabapentin, minus side effects
Nov 14, 2023 10:00am
Strike 3: Aptinyx's pain prospect flunks 3rd midphase trial
Aug 12, 2022 8:23am
No pain, only gain for Vertex as FDA greenlights phase 3 trial
Jul 22, 2022 10:59am
Lexicon touts 'wonderful morning' as pain drug clears phase 2
Jun 30, 2022 10:24am
Vertex gets phase 2 proof-of-concept for non-opioid painkiller
Mar 31, 2022 10:50am